Literature DB >> 11714026

Cloning and sequencing full length of canine Brca2 and Rad51 cDNA.

K Ochiai1, M Morimatsu, N Tomizawa, B Syuto.   

Abstract

Mammary tumors are the most common neoplasm in female dogs, Canis canis, and in women. Mutations in human Brca2 confer an increased risk of female breast cancer. Previous studies have shown that the Brca2 tumor suppressor protein interacts with the recombinational repair protein Rad51. We cloned the full-length cDNA of the canine homologues of Brca2 and Rad51 to obtain a basis for studying their relationship with susceptibility to mammary tumors. The canine Brca2 and Rad51 cDNAs are 11 and 1.5 kb long, encoding 3.471 and 339 amino acids, respectively. The amino acid sequence of canine Brca2 showed 68% homology with the human protein, and 58% homology with a murine protein. There were highly conserved regions in the C-terminus of all three proteins, where the Rad51 interacting domain and putative nuclear localization signals are located. Comparing with the partial genomic sequence previously reported, we found possible nuclear polymorphisms in exon 11, some of which result in amino acid substitutions. On the other hand, canine Rad51 protein had extremely high homology (99%) to the human and murine proteins. Expression of both Brca2 and Rad51 was detected in the mammary gland, suggesting that these two genes interact in the canine mammary gland.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11714026     DOI: 10.1292/jvms.63.1103

Source DB:  PubMed          Journal:  J Vet Med Sci        ISSN: 0916-7250            Impact factor:   1.267


  9 in total

1.  Altered oxidant-antioxidant profile in canine mammary tumours.

Authors:  R Kumaraguruparan; C Balachandran; B Murali Manohar; S Nagini
Journal:  Vet Res Commun       Date:  2005-05       Impact factor: 2.459

2.  Establishment of a PCR analysis method for canine BRCA2.

Authors:  Yasunaga Yoshikawa; Masami Morimatsu; Kazuhiko Ochiai; Kento Okuda; Takahiro Taoda; Seishiro Chikazawa; Asako Shimamura; Toshinori Omi; Makoto Bonkobara; Koichi Orino; Kiyotaka Watanabe
Journal:  BMC Res Notes       Date:  2012-04-03

Review 3.  A monograph proposing the use of canine mammary tumours as a model for the study of hereditary breast cancer susceptibility genes in humans.

Authors:  Katie Goebel; Nancy D Merner
Journal:  Vet Med Sci       Date:  2017-03-21

Review 4.  Canine mammary tumors as a model for human disease.

Authors:  Somaia M Abdelmegeed; Sulma Mohammed
Journal:  Oncol Lett       Date:  2018-04-02       Impact factor: 2.967

Review 5.  Mutations of BRCA2 in canine mammary tumors and their targeting potential in clinical therapy.

Authors:  Pauline Thumser-Henner; Katarzyna J Nytko; Carla Rohrer Bley
Journal:  BMC Vet Res       Date:  2020-01-31       Impact factor: 2.741

Review 6.  DNA damage response proteins in canine cancer as potential research targets in comparative oncology.

Authors:  Beatriz Hernández-Suárez; David A Gillespie; Aleksandra Pawlak
Journal:  Vet Comp Oncol       Date:  2022-01-10       Impact factor: 2.385

7.  Effects of the missense mutations in canine BRCA2 on BRC repeat 3 functions and comparative analyses between canine and human BRC repeat 3.

Authors:  Yasunaga Yoshikawa; Kazuhiko Ochiai; Masami Morimatsu; Yu Suzuki; Seiichi Wada; Takahiro Taoda; Satomi Iwai; Seishiro Chikazawa; Koichi Orino; Kiyotaka Watanabe
Journal:  PLoS One       Date:  2012-10-12       Impact factor: 3.240

8.  Multiplex Gene Expression Profiling of 16 Target Genes in Neoplastic and Non-Neoplastic Canine Mammary Tissues Using Branched-DNA Assay.

Authors:  Florenza Lüder Ripoli; Susanne Conradine Hammer; Annika Mohr; Saskia Willenbrock; Marion Hewicker-Trautwein; Bertram Brenig; Hugo Murua Escobar; Ingo Nolte
Journal:  Int J Mol Sci       Date:  2016-09-21       Impact factor: 5.923

Review 9.  Naturally-Occurring Canine Mammary Tumors as a Translational Model for Human Breast Cancer.

Authors:  Mark Gray; James Meehan; Carlos Martínez-Pérez; Charlene Kay; Arran K Turnbull; Linda R Morrison; Lisa Y Pang; David Argyle
Journal:  Front Oncol       Date:  2020-04-28       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.